11 completed, 4 unknown, 2 recruiting, 1 active not recruiting. 18 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 11, Unknown 4, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 5 | Completed 3, Unknown 2 |
Follow Cabergoline: new trials by email Literature Review of Cabergoline trials Research Report on Cabergoline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Potency of a High Cabergoline Dosage in Microprolactinomas Cabergoline - Prolactinoma, Prolactin Excess | Phase 3 | Recruiting | University of Sao Paulo General Hospital | 70 | 2026-03-04 | 2026-03-13 |
| A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets Cabergoline tablets, Bromocriptine mesylate tablets - Hyperprolactinemia | Phase 3 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 382 | 2025-09-12 | 2025-10-02 |
| Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility Clomiphene Citrate 50mg, Cabergoline Oral Tablet, Placebo Oral Tablet - Infertility | Phase 2 / Phase 3 | Unknown | Assiut University | 120 | 2018-07-01 | 2018-06-08 |
| The Influence of Timing of Cabergoline Initiation on Prevention of OHSS Late Cabergoline 0.5mg, Early Cabergoline 0.5mg - Ovarian Hyperstimulation Syndrome | Phase 3 | Unknown | Mona M Shaban | 75 | 2017-12-20 | 2018-04-10 |
| Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients Cabergoline, Gliclazide - Diabetes | Phase 3 | Unknown | Sherief Abd-Elsalam | 60 | 2017-10-14 | 2018-08-27 |
| Cabergoline in Nonfunctioning Pituitary Adenomas Cabergoline - Pituitary Adenoma, Nonfunctioning Pituitary Adenoma | Phase 3 | Completed | University of Sao Paulo General Hospital | 140 | 2015-02-01 | 2017-09-07 |
| Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection Cabergoline - Infertility | Phase 2 / Phase 3 | Unknown | Kasr El Aini Hospital | 150 | 2014-12-01 | 2016-12-06 |
| Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas cabergoline - Pituitary Neoplasms, Adenoma | Phase 3 | Active not recruiting | St. Olavs Hospital | 60 | 2014-11-01 | 2026-07-21 |
| Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention Oral Cabergoline, Calcium Gluconate - Ovarian Hyperstimulation | Phase 3 | Completed | Benha University | 230 | 2014-10-01 | 2018-03-29 |
| Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Diosmin, Cabergoline - Infertility | Phase 2 / Phase 3 | Completed | Benha University | 200 | 2014-04-01 | 2016-02-02 |
| Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Calcium Dobesilate, Cabergoline - Infertility | Phase 2 / Phase 3 | Completed | Benha University | 200 | 2014-04-01 | 2017-02-16 |
| Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers Cabergoline, Placebo - Ovarian Hyperstimulation Syndrome | Phase 3 | Completed | KK Women's and Children's Hospital | 46 | 2012-04-01 | 2018-08-07 |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2 / Phase 3 | Completed | Universidade Federal do Rio de Janeiro | 21 | 2010-03-01 | 2016-08-22 |
| MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Safinamide (as add-on therapy) - Idiopathic Parkinson's Disease | Phase 3 | Completed | Newron Pharmaceuticals SPA | 679 | 2007-11-01 | 2013-10-29 |
| Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Cabergoline - Cushing's Disease, Corticotroph Adenoma | Phase 3 | Completed | Seth Gordhandas Sunderdas Medical College | 2007-11-01 | 2009-04-29 | |
| Cabergoline Reduces OHSS Cabergoline, MR, Ultrasound - Ovarian Hyperstimulation Syndrome | Phase 3 | Completed | Instituto Valenciano de Infertilidad, IVI VALENCIA | 60 | 2004-04-01 | 2007-02-27 |
| A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS cabergoline, levodopa - Restless Legs Syndrome | Phase 3 | Completed | Pfizer | 361 | 2003-01-01 | 2008-10-29 |
| A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS Cabergoline, Placebo - Restless Legs Syndrome | Phase 3 | Completed | Pfizer | 43 | 2002-11-01 | 2011-04-25 |
Infertility (4) · Ovarian Hyperstimulation Syndrome (3) · Hyperprolactinemia (2) · Pituitary Neoplasms (2) · Prolactinoma (2) · Restless Legs Syndrome (2) · ACTH-Secreting Pituitary Adenoma (1) · Adenoma (1) · Ascites (1) · Diabetes Mellitus (1) · Parkinson Disease (1) · Pituitary ACTH Hypersecretion (1)
Benha University (3) · Pfizer (2) · University of Sao Paulo General Hospital (2) · Assiut University (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Instituto Valenciano de Infertilidad, IVI VALENCIA (1) · KK Women's and Children's Hospital (1) · Kasr El Aini Hospital (1) · Mona M Shaban (1) · Newron Pharmaceuticals SPA (1) · Seth Gordhandas Sunderdas Medical College (1) · Sherief Abd-Elsalam (1) · St. Olavs Hospital (1) · Universidade Federal do Rio de Janeiro (1)
Egypt (6) · Brazil (4) · Germany (2) · India (2) · Sweden (2) · Argentina (1) · Austria (1) · Bulgaria (1) · Canada (1) · Chile (1) · China (1) · Colombia (1) · Croatia (1) · Czechia (1) · Finland (1)
Abla Mohamed Ebeid, Ph D (1) · Ahmed M Kamel, MD (1) · Antonio Pellicer, MD (1) · Ashraf N Elmantwe, MD (1) · Jonathan Willmer, MD (1) · Jouliana Atef Morcos, Msc (1) · Marianne Sybille Hendricks, MBBS, MRCOG (1) · Mona M Shaban, MD (1) · Nalini S Shah, DM (1) · Rafael L Batista, MD (1)
PMID 33851429, PMID 25418156, PMID 27150495, PMID 30540568, PMID 35954244